Class II HLA interactions modulate genetic risk for multiple sclerosis.
Moutsianas L., Jostins L., Beecham AH., Dilthey AT., Xifara DK., Ban M., Shah TS., Patsopoulos NA., Alfredsson L., Anderson CA., Attfield KE., Baranzini SE., Barrett J., Binder TM., Booth D., Buck D., Celius EG., Cotsapas C., D'Alfonso S., Dendrou CA., Donnelly P., Dubois B., Fontaine B., Lar Fugger L., Goris A., Gourraud PA., Graetz C., Hemmer B., Hillert J., International IBD Genetics Consortium (IIBDGC) None., Kockum I., Leslie S., Lill CM., Martinelli-Boneschi F., Oksenberg JR., Olsson T., Oturai A., Saarela J., Søndergaard HB., Spurkland A., Taylor B., Winkelmann J., Zipp F., Haines JL., Pericak-Vance MA., Spencer CC., Stewart G., Hafler DA., Ivinson AJ., Harbo HF., Hauser SL., De Jager PL., Compston A., McCauley JL., Sawcer S., McVean G., International Multiple Sclerosis Genetics Consortium None.
Association studies have greatly refined the understanding of how variation within the human leukocyte antigen (HLA) genes influences risk of multiple sclerosis. However, the extent to which major effects are modulated by interactions is poorly characterized. We analyzed high-density SNP data on 17,465 cases and 30,385 controls from 11 cohorts of European ancestry, in combination with imputation of classical HLA alleles, to build a high-resolution map of HLA genetic risk and assess the evidence for interactions involving classical HLA alleles. Among new and previously identified class II risk alleles (HLA-DRB1*15:01, HLA-DRB1*13:03, HLA-DRB1*03:01, HLA-DRB1*08:01 and HLA-DQB1*03:02) and class I protective alleles (HLA-A*02:01, HLA-B*44:02, HLA-B*38:01 and HLA-B*55:01), we find evidence for two interactions involving pairs of class II alleles: HLA-DQA1*01:01-HLA-DRB1*15:01 and HLA-DQB1*03:01-HLA-DQB1*03:02. We find no evidence for interactions between classical HLA alleles and non-HLA risk-associated variants and estimate a minimal effect of polygenic epistasis in modulating major risk alleles.